Twice each month the CEA Registry Blog lists recently published cost utility studies and associated papers. From the ones listed this time, here's a few in our areas of research interest:
Dakin HA, Wordsworth S, Rogers CA, et al; on behalf of the IVAN Study Investigators. Cost-effectiveness of ranibizumab and bevacizumab for age-related macular degeneration: 2-year findings from the IVAN randomised trial. BMJ Open.x2014 Jul 29;4(7):e005094. PubMed PMID: 25079928.
Burger EA, Sy S, Nygård M, et al. Too late to vaccinate? The incremental benefits and cost-effectiveness of a delayed catch-up program using the 4-valent HPV vaccine in Norway. J Infect Dis. 2014 Jul 23. [Epub ahead of print] PubMed PMID: 25057044.
Zueger PM, Schultz NM, Lee TA. Cost Effectiveness of Liraglutide in Type II Diabetes: A Systematic Review. Pharmacoeconomics. 2014 Jul 23. [Epub ahead of print] PubMed PMID: 25052903.
Jódar-Sánchez F, Ortega F, Parra C, et al. Cost-utility analysis of a telehealth programme for patients with severe chronic obstructive pulmonary disease treated with long-term oxygen therapy. J Telemed Telecare. 2014 Jul 22. [Epub ahead of print] PubMed PMID: 25052387.
